Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Receivables - Other: 2010-2022

Historic Receivables - Other for Arrowhead Pharmaceuticals (ARWR) over the last 8 years, with Sep 2022 value amounting to $4.8 million.

  • Arrowhead Pharmaceuticals' Receivables - Other was N/A to $2.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.5 million, marking a year-over-year change of. This contributed to the annual value of $4.8 million for FY2022, which is 52.00% down from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Receivables - Other stood at $4.8 million for FY2022, which was down 52.00% from $10.0 million recorded in FY2021.
  • Arrowhead Pharmaceuticals' Receivables - Other's 5-year high stood at $10.0 million during FY2021, with a 5-year trough of $700,000 in FY2019.
  • For the 3-year period, Arrowhead Pharmaceuticals' Receivables - Other averaged around $5.2 million, with its median value being $4.8 million (2022).
  • Per our database at Business Quant, Arrowhead Pharmaceuticals' Receivables - Other skyrocketed by 1,150.00% in 2021 and then plummeted by 52.00% in 2022.
  • Over the past 4 years, Arrowhead Pharmaceuticals' Receivables - Other (Yearly) stood at $700,000 in 2019, then climbed by 14.29% to $800,000 in 2020, then soared by 1,150.00% to $10.0 million in 2021, then slumped by 52.00% to $4.8 million in 2022.